|
Age, median (range), y
|
66 (27–87)
|
|
Race, No. (%)
|
|
White
|
142 (90.5)
|
|
Black or African American
|
7 (4.5)
|
|
Asian
|
3 (1.9)
|
|
Native Hawaiian/Pacific Islander
|
1 (0.6)
|
|
Other
|
4 (2.5)
|
|
Diagnosis, No. (%)
|
|
Adenocarcinoma
|
108 (68.8)
|
|
Squamous
|
45 (28.7)
|
|
Other
|
4 (2.5)
|
|
Sex, No. (%)
|
|
Female
|
74 (47.1)
|
|
Male
|
83 (52.9)
|
|
Prior chemotherapy lines, No. (%)
|
|
0
|
29 (18.5)
|
|
1
|
78 (49.7)
|
|
2
|
34 (21.7)
|
|
≥3
|
16 (10.2)
|
|
ECOG performance status, No. (%)
|
|
0
|
40 (25.5)
|
|
1
|
75 (47.8)
|
|
2
|
37 (23.5)
|
|
3
|
5 (3.2)
|
|
CNS disease, No. (%)
|
|
Yes
|
54 (34.4)
|
|
No
|
103 (65.6)
|
|
Immunotherapy drug, No. (%)
|
|
Nivolumab
|
146 (93.0)
|
|
Pembrolizumab
|
11 (7.0)
|
|
Immune adverse effects, No. (%)
|
|
No
|
98 (62.4)
|
|
Yes
|
59 (37.6)
|
